JP2012095641A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012095641A5 JP2012095641A5 JP2011160400A JP2011160400A JP2012095641A5 JP 2012095641 A5 JP2012095641 A5 JP 2012095641A5 JP 2011160400 A JP2011160400 A JP 2011160400A JP 2011160400 A JP2011160400 A JP 2011160400A JP 2012095641 A5 JP2012095641 A5 JP 2012095641A5
- Authority
- JP
- Japan
- Prior art keywords
- variant
- substitution
- vivo
- group
- glycosylation site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000006467 substitution reaction Methods 0.000 claims 27
- 238000001727 in vivo Methods 0.000 claims 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 230000004988 N-glycosylation Effects 0.000 claims 15
- 230000004048 modification Effects 0.000 claims 14
- 238000012986 modification Methods 0.000 claims 14
- 208000032843 Hemorrhage Diseases 0.000 claims 8
- 208000034158 bleeding Diseases 0.000 claims 8
- 230000000740 bleeding effect Effects 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 230000013595 glycosylation Effects 0.000 claims 6
- 238000006206 glycosylation reaction Methods 0.000 claims 6
- 238000003780 insertion Methods 0.000 claims 5
- 230000037431 insertion Effects 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 208000031220 Hemophilia Diseases 0.000 claims 4
- 208000009292 Hemophilia A Diseases 0.000 claims 4
- 208000014674 injury Diseases 0.000 claims 4
- 125000005647 linker group Chemical group 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 230000008733 trauma Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 230000004075 alteration Effects 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000035602 clotting Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000002271 resection Methods 0.000 claims 2
- 102220253478 rs1553261891 Human genes 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 102220595361 Anamorsin_A34E_mutation Human genes 0.000 claims 1
- 102220594400 HLA class I histocompatibility antigen, C alpha chain_D33F_mutation Human genes 0.000 claims 1
- 230000004989 O-glycosylation Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45654703P | 2003-03-20 | 2003-03-20 | |
| US60/456,547 | 2003-03-20 | ||
| US47970803P | 2003-06-19 | 2003-06-19 | |
| US60/479,708 | 2003-06-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006504332A Division JP4847856B2 (ja) | 2003-03-20 | 2004-03-22 | ＦＶＩＩおよびＦＶＩＩａの変種 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012095641A JP2012095641A (ja) | 2012-05-24 |
| JP2012095641A5 true JP2012095641A5 (enExample) | 2012-10-11 |
| JP2012095641A6 JP2012095641A6 (ja) | 2018-11-01 |
Family
ID=33032721
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006504332A Expired - Fee Related JP4847856B2 (ja) | 2003-03-20 | 2004-03-22 | ＦＶＩＩおよびＦＶＩＩａの変種 |
| JP2011160400A Pending JP2012095641A (ja) | 2003-03-20 | 2011-07-22 | ＦＶＩＩおよびＦＶＩＩａの変種 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006504332A Expired - Fee Related JP4847856B2 (ja) | 2003-03-20 | 2004-03-22 | ＦＶＩＩおよびＦＶＩＩａの変種 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7771996B2 (enExample) |
| EP (2) | EP2085470B1 (enExample) |
| JP (2) | JP4847856B2 (enExample) |
| AT (1) | ATE431403T1 (enExample) |
| AU (2) | AU2004221761B2 (enExample) |
| CA (1) | CA2519873C (enExample) |
| DE (1) | DE602004021099D1 (enExample) |
| DK (2) | DK1608745T3 (enExample) |
| ES (2) | ES2386010T3 (enExample) |
| WO (1) | WO2004083361A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7247708B2 (en) | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6747003B1 (en) | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| PL204285B1 (pl) * | 2000-02-11 | 2009-12-31 | Bayer Healthcare Llc | Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego |
| US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7812132B2 (en) | 2000-04-28 | 2010-10-12 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US20030211094A1 (en) | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| BR0309576A (pt) * | 2002-04-30 | 2005-02-09 | Maxygen Holdings Ltd | Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável |
| AU2004221761B2 (en) | 2003-03-20 | 2010-01-07 | Bayer Healthcare Llc | FVII or FVIIa variants |
| DE602004025576D1 (de) | 2003-06-19 | 2010-04-01 | Bayer Healthcare Llc | Varianten der faktor-vii- oder -viia-gla-domäne |
| MX2007001294A (es) | 2004-08-17 | 2008-03-04 | Zlb Behring Gmbh | Polipeptidos modificados que dependen de vitamina k. |
| US20080188400A1 (en) * | 2005-04-26 | 2008-08-07 | Maxygen Holdings Ltd. | Methods For Treating Bleeding |
| JP5335422B2 (ja) | 2005-06-17 | 2013-11-06 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化 |
| JP5147692B2 (ja) | 2005-07-13 | 2013-02-20 | ノボ ノルディスク ヘルス ケア アーゲー | 治療用タンパク質生成のための宿主細胞タンパク質ノックアウト細胞 |
| EP1924689B1 (en) | 2005-09-01 | 2014-08-13 | Novo Nordisk Health Care AG | Hydrophobic interaction chromatography purification of factor vii polypeptides |
| JP5690047B2 (ja) | 2005-09-14 | 2015-03-25 | ノボ ノルディスク ヘルス ケア アーゲー | ヒト凝固第ｖｉｉ因子ポリペプチド |
| WO2007104317A1 (en) * | 2006-03-16 | 2007-09-20 | Drugrecure Aps | Methods for local treatment with factor vii |
| EP2059527B1 (en) | 2006-09-01 | 2014-12-03 | Novo Nordisk Health Care AG | Modified glycoproteins |
| AU2013204377B2 (en) * | 2007-04-13 | 2015-07-16 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides and uses thereof |
| WO2008127702A2 (en) * | 2007-04-13 | 2008-10-23 | Catalyst Biosciences, Inc. | Modified factor vii polypetides and uses thereof |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| TWI595004B (zh) | 2010-11-03 | 2017-08-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| MX380585B (es) * | 2012-12-24 | 2025-03-12 | Coagulant Therapeutics Corp | Polipeptidos del factor vii de acción corta. |
| AU2018338608B2 (en) | 2017-09-27 | 2025-09-11 | Sigilon Therapeutics, Inc. | Methods, compositions, and implantable elements comprising active cells |
| MX2020010369A (es) | 2018-04-04 | 2020-10-22 | Sigilon Therapeutics Inc | Particulas implantables y metodos relacionados. |
| WO2019195056A1 (en) | 2018-04-04 | 2019-10-10 | Sigilon Therapeutics, Inc. | Methods, compositions, and implantable elements comprising stem cells |
| UY38389A (es) | 2018-09-27 | 2020-04-30 | Sigilon Therapeutics Inc | Dispositivos implantables para terapia celular y métodos relacionados |
| US20210069306A1 (en) | 2019-08-15 | 2021-03-11 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration and on-demand treatment |
| WO2024081309A1 (en) | 2022-10-11 | 2024-04-18 | Sigilon Therapeutics, Inc. | Engineered cells and implantable elements for treatment of disease |
| CN120659872A (zh) | 2022-10-11 | 2025-09-16 | 西吉隆医疗股份有限公司 | 用于治疗疾病的经工程化的细胞和可植入元件 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| US5180583A (en) | 1985-11-26 | 1993-01-19 | Hedner Ulla K E | Method for the treatment of bleeding disorders |
| US5258288A (en) | 1986-07-25 | 1993-11-02 | Genzyme Corporation | Vector containing DNA encoding mature human protein S |
| DK323587D0 (da) | 1987-06-25 | 1987-06-25 | Novo Industri As | Protein |
| PT87688B (pt) | 1987-06-12 | 1992-09-30 | Hoechst Japan | Processo para a preparacao de proteina hibrida c |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5648254A (en) | 1988-01-15 | 1997-07-15 | Zymogenetics, Inc. | Co-expression in eukaryotic cells |
| JPH0246296A (ja) | 1988-08-09 | 1990-02-15 | Hoechst Japan Ltd | 雑種プロテインｃ及びその製造方法 |
| US5218092A (en) | 1988-09-29 | 1993-06-08 | Kyowa Hakko Kogyo Co., Ltd. | Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains |
| US5041376A (en) | 1988-12-09 | 1991-08-20 | The Board Of Regents Of The University Of Texas System | Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins |
| US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
| US5093317A (en) | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
| US5077214A (en) | 1989-07-07 | 1991-12-31 | The Texas A&M University System | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells |
| US5580560A (en) | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| US5225537A (en) | 1989-12-29 | 1993-07-06 | Zymogenetics, Inc. | Methods for producing hybrid phospholipid-binding proteins |
| CA2073859A1 (en) | 1990-01-26 | 1991-07-27 | Falko-Guenter Falkner | Recombinantly produced blood factors and process for the expression of said blood factors, as well as vaccinia virus recombinants used in said process |
| CA2074839C (en) | 1990-01-29 | 2000-11-14 | Kathleen L. Berkner | Modified factor vii anticoagulant proteins |
| US5583107A (en) | 1990-09-04 | 1996-12-10 | Cor Therapeutics, Inc. | Agents affecting thrombosis and hemostasis |
| US5531916A (en) | 1990-10-03 | 1996-07-02 | E. I. Du Pont De Nemours And Company | Hydrofluorocarbon cleaning compositions |
| EP0785273A1 (en) | 1990-11-26 | 1997-07-23 | Genetics Institute, Inc. | Paired basic amino acid converting enzyme and DNA sequence encoding it |
| US5817788A (en) | 1991-02-28 | 1998-10-06 | Zymogenetics, Inc. | Modified factor VII |
| US5833982A (en) | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
| US5861374A (en) | 1991-02-28 | 1999-01-19 | Novo Nordisk A/S | Modified Factor VII |
| US5788965A (en) | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
| JP3459416B2 (ja) | 1991-02-28 | 2003-10-20 | ザイモジェネティクス，インコーポレイティド | 修飾されたファクター▲ｖｉｉ▼ |
| US5504064A (en) | 1991-04-10 | 1996-04-02 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with an activator of FVII |
| JPH0720127A (ja) | 1993-05-07 | 1995-01-24 | Eisai Co Ltd | 各種ｐｉｖｋａの測定方法および測定試薬 |
| PT699075E (pt) | 1993-05-21 | 2002-05-31 | Novo Nordisk As | Factor vii modificado para inibicao de restenose vascular e de deposicao de plaquetas |
| DE19531637A1 (de) | 1995-08-28 | 1997-03-06 | Immuno Ag | Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung |
| CA2271232C (en) | 1996-11-08 | 2005-02-22 | Oklahoma Medical Research Foundation | Modified protein c and methods of use thereof |
| US5837843A (en) | 1996-11-08 | 1998-11-17 | Oklahoma Medical Research Foundation | Modified protein C |
| IL130908A0 (en) * | 1997-01-22 | 2001-01-28 | Univ Texas | Tissue-factor (tf) compositions for coagulation and tumor treatment |
| AU5773798A (en) | 1997-01-29 | 1998-08-18 | Polymasc Pharmaceuticals Plc | Pegylation process |
| EP1017794A1 (en) | 1997-02-06 | 2000-07-12 | Novo Nordisk A/S | Polypeptide-polymer conjugates having added and/or removed attachment groups |
| US6475725B1 (en) | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
| AT407255B (de) | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
| IL133974A0 (en) | 1997-07-14 | 2001-04-30 | Bolder Biotechnology Inc | Derivatives of growth hormone and related proteins |
| EP1005361B1 (en) | 1997-07-18 | 2010-01-06 | Novo Nordisk Health Care AG | USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ENDOTHELIAL DYSFUNKTION AND FOR THE INHIBITION OF ANGIOGENESIS RESPECTIVELY |
| US6693075B1 (en) | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6747003B1 (en) | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6017882A (en) | 1997-10-23 | 2000-01-25 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7247708B2 (en) | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| BR9910023A (pt) | 1998-04-28 | 2000-12-26 | Applied Research Systems | Conjugados de poliol-ifn-beta |
| AT408613B (de) | 1998-06-17 | 2002-01-25 | Immuno Ag | Pharmazeutisches faktor vii-präparat |
| DE69916306T2 (de) | 1998-10-30 | 2005-05-04 | Novozymes A/S | Niedrigallergene proteinvarianten |
| WO2000026354A1 (en) | 1998-10-30 | 2000-05-11 | Novozymes A/S | Glycosylated proteins having reduced allergenicity |
| JP4463988B2 (ja) | 1998-11-06 | 2010-05-19 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Ｖｉｉ因子の生産方法 |
| AU3629800A (en) | 1999-03-16 | 2000-10-04 | Children's Hospital Of Philadelphia, The | Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors |
| PL204285B1 (pl) | 2000-02-11 | 2009-12-31 | Bayer Healthcare Llc | Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego |
| US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| JP5090605B2 (ja) * | 2000-05-03 | 2012-12-05 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 凝固因子ｖｉｉの皮下投与 |
| EP1282693B1 (en) | 2000-05-03 | 2010-10-20 | Novo Nordisk Health Care AG | Human coagulation factor vii variants |
| US7160540B2 (en) | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
| US20030211094A1 (en) | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| US6423826B1 (en) | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
| IL154520A0 (en) | 2000-09-13 | 2003-09-17 | Novo Nordisk As | Human coagulation factor vii variants |
| CZ2003611A3 (cs) | 2000-09-13 | 2003-08-13 | Novo Nordisk A/S | Varianty lidského koagulačního faktoru VII |
| AU9165201A (en) | 2000-10-02 | 2002-04-15 | Novo Nordisk As | Factor vii glycoforms |
| WO2002038162A1 (en) | 2000-11-09 | 2002-05-16 | The Scripps Research Institute | MODIFIED FACTOR VIIa |
| CZ20032454A3 (en) | 2001-03-22 | 2004-03-17 | Novo Nordisk Health Care Ag | Coagulation factor vii derivative |
| ES2376694T3 (es) | 2001-09-27 | 2012-03-16 | Novo Nordisk Health Care Ag | Polipã‰ptidos del factor vii de coagulaciã“n humano. |
| AU2002336919A1 (en) | 2001-11-02 | 2003-05-12 | Novo Nordisk Health Care Ag | Human coagulation factor vii polypeptides |
| ES2325653T3 (es) | 2001-12-21 | 2009-09-11 | Novo Nordisk Health Care Ag | Composicion liquida de polipeptidos del factor vii. |
| BR0309576A (pt) | 2002-04-30 | 2005-02-09 | Maxygen Holdings Ltd | Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável |
| CA2502162C (en) | 2002-09-30 | 2014-04-15 | Bayer Healthcare Llc | Fvii or fviia variants having increased clotting activity |
| AU2004221761B2 (en) | 2003-03-20 | 2010-01-07 | Bayer Healthcare Llc | FVII or FVIIa variants |
| DE602004025576D1 (de) | 2003-06-19 | 2010-04-01 | Bayer Healthcare Llc | Varianten der faktor-vii- oder -viia-gla-domäne |
| WO2005023308A1 (en) * | 2003-09-05 | 2005-03-17 | Maxygen Holdings Ltd. | Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins |
-
2004
- 2004-03-22 AU AU2004221761A patent/AU2004221761B2/en not_active Ceased
- 2004-03-22 ES ES09075170T patent/ES2386010T3/es not_active Expired - Lifetime
- 2004-03-22 ES ES04722232T patent/ES2327044T3/es not_active Expired - Lifetime
- 2004-03-22 AT AT04722232T patent/ATE431403T1/de not_active IP Right Cessation
- 2004-03-22 DE DE602004021099T patent/DE602004021099D1/de not_active Expired - Lifetime
- 2004-03-22 DK DK04722232T patent/DK1608745T3/da active
- 2004-03-22 CA CA2519873A patent/CA2519873C/en not_active Expired - Fee Related
- 2004-03-22 EP EP09075170A patent/EP2085470B1/en not_active Expired - Lifetime
- 2004-03-22 JP JP2006504332A patent/JP4847856B2/ja not_active Expired - Fee Related
- 2004-03-22 US US10/549,506 patent/US7771996B2/en not_active Expired - Fee Related
- 2004-03-22 WO PCT/DK2004/000193 patent/WO2004083361A2/en not_active Ceased
- 2004-03-22 EP EP04722232A patent/EP1608745B1/en not_active Expired - Lifetime
- 2004-03-22 DK DK09075170.2T patent/DK2085470T3/da active
-
2010
- 2010-03-25 AU AU2010201201A patent/AU2010201201A1/en not_active Abandoned
- 2010-05-05 US US12/774,560 patent/US20100330669A1/en not_active Abandoned
-
2011
- 2011-07-22 JP JP2011160400A patent/JP2012095641A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012095641A5 (enExample) | ||
| JP2006521098A5 (enExample) | ||
| JP2012105650A5 (enExample) | ||
| CA2519873A1 (en) | Fvii or fviia variants | |
| JP2006527982A5 (enExample) | ||
| RU2004134726A (ru) | Варианты полипептида фактора vii или viia | |
| JP2006517089A5 (enExample) | ||
| AU2016280867B2 (en) | Long-acting coagulation factors and methods of producing same | |
| CA2690218C (en) | Use of vwf stabilized fviii preparations and of vwf preparations without fviii for extravascular administration in the therapy and prophylactic treatment of bleeding disorders | |
| JP2014513952A5 (enExample) | ||
| TW200942258A (en) | Factor VII polypeptides that are modified and uses thereof | |
| AU2016202829B2 (en) | Long-acting coagulation factors and methods of producing same | |
| JP2020010717A (ja) | 補因子の非存在下で凝固活性を有する、及び／又は、第ｉｘ因子凝固活性が増加した第ｉｘ因子変異体、並びに、出血性疾患を処置するためのその使用 | |
| PT2147096E (pt) | Polipéptidos do factor vii modificados e suas utilizações | |
| JP2011517942A5 (enExample) | ||
| HRP20100264T1 (hr) | Varijante gla domene faktora vii ili viia | |
| KR20160002848A (ko) | 표적 세포 내에서 치료적 단백질의 표적화된 생산을 위한 시스템 및 방법 | |
| JP7610338B2 (ja) | 血友病ａの遺伝子療法のための発現が上昇した組換えｆｖｉｉｉバリアントをコードするウイルスベクター | |
| RU2012105915A (ru) | ПОЛИПЕПТИДЫ, СЕЛЕКТИВНЫЕ В ОТНОШЕНИИ ИНТЕГРИНА ανβ, КОНЪЮГИРОВАННЫЕ С ВАРИАНТОМ ЧЕЛОВЕЧЕСКОГО СЫВОРОТОЧНОГО АЛЬБУМИНА (HSA), И ИХ ФАРМАЦЕВТИЧЕСКИЕ ПРИМЕНЕНИЯ | |
| RU2013151875A (ru) | Модифицированная кислая альфа глюкозидаза с ускоренным процессингом | |
| WO2007022784A2 (en) | Liquid factor vii composition | |
| JP2017502036A (ja) | 血友病の予防的処置のための第ｉｘ因子を含む融合タンパク質およびその方法 | |
| JP2013538863A5 (enExample) | ||
| WO2021030787A1 (en) | Modified factor vii polypeptides for subcutaneous administration and on-demand treatment | |
| JP2021530524A (ja) | 発現が増強された組換えｆｖｉｉｉ変異体をコードするウイルスベクターを使用する血友病ａの遺伝子療法 |